查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827233

癌症分析市場（按癌症類型、技術、樣本類型、生物標記類型、應用和最終用戶分類）—2025-2032 年全球預測

Cancer Profiling Market by Cancer Type, Technology, Sample Type, Biomarker Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年癌症分析市場規模將成長至 288.1 億美元，複合年成長率為 11.73%。

主要市場統計數據
基準年2024年 118.6億美元
預計2025年 131.5億美元
預測年份：2032年 288.1億美元
複合年成長率（%） 11.73%

簡要總結癌症分析領域的最新技術、臨床和操作動態，以支援診斷和治療相關人員的策略決策

本執行摘要總結了癌症分析技術的最新進展、臨床應用和最終用戶採用趨勢，旨在幫助診斷、治療和研究相關人員進行策略規劃。它重點關注技術創新與臨床需求的交匯，強調不斷發展的檢測能力、樣本工作流程和生物標記策略如何重塑診斷決策和轉化研究途徑。

本書將次世代定序、分子檢測和液態切片方法的最新進展與不斷變化的供應鏈動態和監管預期相結合，重點闡述了其對臨床實驗室、醫院、藥物開發和研究機構的實際意義。本書將這些進展置於精準腫瘤學、基於分子資訊的治療方法選擇和真實世界證據生成等更廣泛的醫療保健需求之中。本書旨在為讀者提供簡潔實用的基礎，以便將投資、營運和臨床策略與當今癌症分析領域最具影響力的趨勢相結合。

摘要將技術分析與終端用戶觀點相結合，揭示了決定哪些創新技術能夠實現常規臨床效用的關鍵依賴因素，例如試劑可用性、樣本處理標準和數據解讀基礎設施。本內容旨在幫助企業高管、臨床領導者和實驗室主任更好地理解並調整技術選擇和夥伴關係機會，使其與不斷變化的臨床需求和監管趨勢相契合。

定序、非侵入性採樣和綜合生物標記策略的快速創新如何重新定義癌症分析的臨床工作流程和商業性夥伴關係

癌症分析正在經歷一場變革，這得益於定序保真度、多重檢測和樣本間分析模型的突破，這些突破拓展了臨床醫生的實用窗口。長讀長和短讀長定序方法的進展正被整合到診斷流程中，透過捕捉先前難以捉摸的複雜基因組重排和結構突變，可以更深入地對腫瘤生物學和抗藥性機制進行分層。

同時，非侵入性取樣和液態切片靈敏度的不斷提升，擴大了效用，而免疫組織化學和螢光原位雜合反應則持續為治療決策提供基於組織的快速資訊。這些技術進步，加上增強型生物資訊工具鏈的支持，降低了解讀取的差異性，並加快了周轉時間，正在促進其在診斷實驗室和醫院的廣泛應用。

隨著實驗室創新的推進，模組化工作流程正逐漸成為主流，重點在於互通性、標準化報告和跨平台檢驗。相關人員對伴隨診斷和藥物基因體學洞察的需求，以及這些洞察能否直接指導治療方法的選擇，推動了檢測開發商和製藥公司之間更緊密的合作。結果是，診斷模式發生了轉變，轉向整合診斷生態系統，該生態系統結合了基於DNA、RNA和蛋白質的生物標記物，能夠提供多方面的臨床資訊。

最終，這些轉變的累積效應正在改變整個治療過程中的價值提案。早期準確的分子表徵減少了診斷的不確定性，使臨床試驗的精准入組成為可能，並支持自適應治療策略。這對市場參與企業的影響顯而易見：成功取決於能否大規模地提供可重複且具有臨床操作性的結果，並由強大的物流支持、合規的數據管治以及永續的商業模式提供支持，從而協調供應商、付款人和開發者的獎勵。

預測 2025 年關稅將如何改變診斷和研究領域癌症分析相關人員的供應鏈、定價權和策略採購選擇

2025年美國新關稅的實施將對癌症分析相關人員產生多方面的影響，影響供應鏈、籌資策略和跨國合作。對於定序儀器和檢測試劑套件製造商而言，部分組件和成品的進口關稅上調可能會增加到岸成本，迫使供應商重新評估定價、採購和庫存。此類發展將迫使診斷實驗室和醫院重新評估試劑採購週期，並協商達成協議，在不影響臨床通量的情況下，確保獲得高價值檢測試劑。

除了直接的成本效益外，關稅還可能促使企業採取策略性應對措施，例如供應商多元化、關鍵製造流程的近岸外包以及重視區域配送中心，以降低前置作業時間的波動性。雖然這些調整措施可能在中期內增強韌性，但它們需要前期投資和營運變革，這可能會暫時中斷服務交付。同時，依賴進口專用試劑和設備的研究機構和製藥公司可能會面臨計劃延遲和研究成本增加的問題，這可能會影響生物標記檢驗和伴隨診斷的開發進度。

關稅主導的價格調整也會對長讀長定序和高內涵平台等先進技術的採用產生下游效應。資源受限的醫療保健提供者可能會優先考慮成熟的低成本方法，例如免疫組織化學和聚合酵素鏈鎖反應，從而減緩採用高成本但臨床有益的技術的速度。相反，支付方和醫療系統可能會加速在卓越中心內整合檢測，以在控制整體支出的同時，保持獲得全面分析的機會。

在監管和政策方面，關稅可以促進產業界和政府之間就生物技術供應鏈的戰略重要性展開對話，並加速對國內製造業、官民合作關係以及針對本地能力的定向投資的獎勵。此類政策因應措施有可能緩解長期脆弱性，但也將塑造競爭動態和製造業專有技術的全球分佈。綜合關稅環境凸顯了供應鏈透明度、靈活的籌資策略以及積極的相關人員參與的重要性，以確保高品質癌症分析服務的持續性。

細分分析揭示了癌症類型、技術選擇、樣本基質、生物標記類別、應用目標和最終用戶要求如何決定臨床和商業優先級

從細分領域獲得的洞察揭示了癌症分析領域的融合點，在這些融合點中，臨床效用、技術成熟度和最終用戶需求為整個癌症分析領域帶來了機會和風險。血液學工作流程強調檢測白血病、淋巴瘤和多發性骨髓瘤中的特異性融合事件、克隆動態和微小殘留疾病，而固態腫瘤分析則強調乳癌、結直腸癌、肺癌和前列腺癌中的可操作突變和腫瘤異質性。這些不同的臨床目標影響實驗室實踐中檢測方法的選擇、樣本處理和報告的精細度。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 循環腫瘤DNA液態生物檢體檢測方法在腫瘤治療中的即時監測
  • 實施結合基因組學、蛋白質組學和代謝體學數據的多體學分析平台，以全面表徵腫瘤
  • 基於次世代定序的癌症標靶治療伴隨診斷的監管核准趨勢
  • 擴展人工智慧和機器學習演算法來解釋複雜的癌症分析資料集並預測患者結果
  • 開發一種經濟高效的照護現場分子分析設備，用於資源有限環境下的早期癌症檢測
  • 新興表觀遺傳生物標記組可對固態腫瘤適應症的患者對免疫療法的反應進行分層
  • 生物製藥和診斷公司合作開發用於微量殘存疾病監測的液態生物檢體檢測方法
  • 將空間轉錄組學整合到臨床工作流程中，以實現腫瘤微環境異質性的高解析度映射

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

第8章 癌症分析市場（依癌症類型）

  • 造血系統惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌

第9章：癌症分析市場（依技術）

  • 螢光原位雜合反應
  • 免疫組織化學
  • 微陣列
  • 次世代定序
    • 長讀定序
    • 短讀定序
  • 聚合酵素鏈鎖反應（PCR）

第 10 章癌症分析市場（依標本類型）

  • 血
    • 電漿
    • 血清
    • 全血
  • 唾液
  • 尿

第 11 章癌症分析市場（依生物標記類型）

  • 基於DNA
  • 蛋白質類
  • 基於RNA

第12章 癌症分析市場（按應用）

  • 診斷
  • 監控
    • 液態生物檢體
    • 微量殘存疾病
  • 預後
  • 研究
  • 治療方法方案
    • 伴隨診斷
    • 藥物基因組學

第13章 癌症分析市場（按最終用戶）

  • 診斷實驗室
  • 醫院
  • 製藥公司
  • 研究所

第14章 癌症分析市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 15 章癌症分析市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國癌症分析市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章競爭格局

  • 市佔率分析（2024年）
  • FPNV定位矩陣（2024年）
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific Inc.
    • 4basecare Onco Solutions Private Limited
    • ACT Genomics Co., Ltd. by Prenetics Global Limited
    • Agendia, Inc.
    • Agilent Technologies, Inc.
    • BostonGene Corporation
    • Caris Life Sciences
    • Exact Sciences Corporation
    • GENINUS Inc.
    • Genomic Life
    • GenScript Biotech Corporation
    • Guardant Health, Inc.
    • Hologic, Inc.
    • HTG Molecular Diagnostics, Inc.
    • Illumina, Inc.
    • IMBdx, Inc.
    • Laboratory Corporation of America Holdings
    • Lucence Health, Inc.
    • Merck KGaA
    • NanoString Technologies, Inc.
    • Neogenomics, Inc.
    • Nonacus Limited
    • OncoDNA SA
    • Oncompass Medicine Hungary Kft.
    • Paragon Genomics, Inc.
    • Personalis, Inc.
    • Perthera, Inc.
    • Qiagen NV
    • Renovaro Biosciences Inc.
    • Strand Life Sciences
    • Sysmex Corporation
    • Takara Bio Inc.
    • Tempus Labs Inc.
Product Code: MRR-1A1A064C046A

The Cancer Profiling Market is projected to grow by USD 28.81 billion at a CAGR of 11.73% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 11.86 billion
Estimated Year [2025] USD 13.15 billion
Forecast Year [2032] USD 28.81 billion
CAGR (%) 11.73%

A concise synthesis of recent technological, clinical, and operational dynamics in cancer profiling that frames strategic decisions for diagnostics and therapeutic stakeholders

This executive summary synthesizes contemporary developments in cancer profiling technologies, clinical applications, and end-user adoption trends to inform strategic planning for stakeholders across diagnostics, therapeutics, and research. It focuses on the intersection of technological innovation and clinical need, highlighting how evolving assay capabilities, sample workflows, and biomarker strategies are reshaping diagnostic decision-making and translational research pathways.

The narrative emphasizes practical implications for clinical laboratories, hospitals, pharmaceutical developers, and research institutions by integrating recent advances in next-generation sequencing, molecular assays, and liquid biopsy approaches with shifting supply chain dynamics and regulatory expectations. It situates these developments within broader healthcare imperatives such as precision oncology, molecularly informed therapy selection, and real-world evidence generation. The intent is to provide readers with a concise, actionable foundation for aligning investment, operational, and clinical strategies with the most impactful trends in cancer profiling today.

Through a combination of technology-focused analysis and end-user perspectives, the summary also identifies critical dependencies-such as reagent availability, sample handling standards, and data interpretation infrastructures-that will determine which innovations achieve routine clinical utility. The content is designed to be relevant for executives, clinical leaders, and laboratory directors seeking to weigh technology choices and partnership opportunities against evolving clinical demands and regulatory pathways.

How rapid innovations in sequencing, noninvasive sampling, and integrated biomarker strategies are redefining clinical workflows and commercial partnerships in cancer profiling

Cancer profiling is undergoing transformative shifts driven by leaps in sequencing fidelity, assay multiplexing, and sample-agnostic analytic models that expand the actionable window for clinicians. Advances in long-read and short-read sequencing modalities are being integrated into diagnostic pipelines to capture complex genomic rearrangements and structural variants that were previously elusive, enabling finer stratification of tumor biology and resistance mechanisms.

Concurrently, improvements in noninvasive sampling and liquid biopsy sensitivity are extending the utility of monitoring and minimal residual disease detection, while immunohistochemistry and fluorescence in situ hybridization continue to provide rapid, tissue-based context for therapeutic decisions. These technological refinements are supported by enhanced bioinformatics toolchains that reduce interpretive variability and accelerate turnaround times, fostering broader adoption among diagnostic laboratories and hospitals.

Parallel to laboratory innovations, the landscape is shifting toward modular workflows that prioritize interoperability, standardized reporting, and cross-platform validation. This movement is reinforced by stakeholders' demand for companion diagnostics and pharmacogenomic insights that directly inform therapy selection, driving closer collaboration between assay developers and pharmaceutical companies. As a result, the paradigm is moving from isolated tests toward integrated diagnostic ecosystems that combine DNA-based, RNA-based, and protein-based biomarkers to deliver multidimensional clinical intelligence.

Finally, the cumulative effect of these shifts is altering value propositions across the care continuum: early and accurate molecular characterization reduces diagnostic odysseys, enables targeted enrollment into clinical trials, and supports adaptive treatment strategies. The implication for market participants is clear: success will depend on delivering reproducible, clinically actionable results at scale, supported by robust logistics, compliant data governance, and sustainable commercial models that align incentives across providers, payers, and developers.

Anticipating how 2025 tariff measures reshape supply chains, pricing dynamics, and strategic sourcing choices for cancer profiling stakeholders across diagnostics and research

The introduction of new tariff measures in the United States in 2025 presents a multifaceted set of implications for cancer profiling stakeholders, affecting supply chains, procurement strategies, and cross-border collaboration. For manufacturers of sequencing instruments and assay kits, increased import duties on select components and finished goods can elevate landed costs, prompting suppliers to reassess pricing, sourcing, and inventory practices. This dynamic will exert pressure on diagnostic laboratories and hospitals to reevaluate reagent purchasing cycles and to negotiate contracts that preserve access to high-value assays without compromising clinical throughput.

Beyond direct cost effects, tariffs can catalyze strategic responses such as supplier diversification, nearshoring of critical manufacturing steps, and greater emphasis on regional distribution hubs to mitigate lead-time volatility. These adaptations may improve resilience in the medium term but require upfront capital and operational changes that can temporarily disrupt service delivery. In parallel, research institutes and pharmaceutical companies that depend on imported specialized reagents and instrumentation may face project delays or increased study costs, influencing timelines for biomarker validation and companion diagnostic development.

Tariff-driven price adjustments also have downstream implications for adoption of advanced technologies such as long-read sequencing or high-content platforms. Providers in resource-constrained settings may prioritize established, lower-cost methodologies like immunohistochemistry and polymerase chain reaction, slowing diffusion of higher-cost but clinically informative technologies. Conversely, payers and health systems may accelerate consolidation of testing within centers of excellence to preserve access to comprehensive profiling while containing overall expenditure.

On the regulatory and policy front, tariffs can prompt dialogue between industry and government about strategic importance of biotech supply chains, potentially accelerating incentives for domestic manufacturing, public-private partnerships, and targeted investments in local capacity. These policy responses may reduce long-term vulnerability but will also shape competitive dynamics and the distribution of manufacturing expertise globally. Collectively, the tariff environment underscores the importance of supply chain transparency, flexible sourcing strategies, and proactive stakeholder engagement to ensure continuity of high-quality cancer profiling services.

Segment-level analysis revealing how cancer type, technology choice, sample matrix, biomarker class, application purpose, and end-user requirements jointly determine clinical and commercial priorities

Insights derived from segmentation illuminate where clinical utility, technology maturity, and end-user needs converge to create opportunity and risk across the cancer profiling landscape. Based on cancer type, differences between hematologic malignancies and solid tumors drive distinct testing priorities: hematologic workflows emphasize detection of specific fusion events, clonal dynamics, and minimal residual disease across leukemia, lymphoma, and multiple myeloma, while solid tumor profiling concentrates on actionable mutations and tumor heterogeneity within breast, colorectal, lung, and prostate cancers. These divergent clinical goals inform assay selection, sample handling, and reporting granularity in laboratory operations.

Based on technology, the diagnostic toolkit spans fluorescence in situ hybridization, immunohistochemistry, microarray platforms, next-generation sequencing, and polymerase chain reaction. Within next-generation sequencing, the emergence of both long-read sequencing and short-read sequencing enables complementary interrogation of genomic complexity: short-read approaches provide high-throughput mutation detection and cost-efficiency, while long-read methods resolve structural variants and repetitive regions that have clinical relevance for specific tumor types. The choice of technology is shaped by clinical indication, turnaround time requirements, and the analytic sensitivity necessary for monitoring and early detection.

Based on sample type, blood, saliva, and urine each offer unique advantages and constraints. Blood-derived analyses-including plasma, serum, and whole blood-support both tumor genotyping and longitudinal monitoring via circulating tumor DNA, whereas saliva and urine present noninvasive alternatives for certain tumor types and patient populations. Sample matrices influence pre-analytical workflows, cold chain logistics, and interpretation frameworks, requiring laboratories to standardize collection protocols to preserve assay performance.

Based on biomarker type, DNA-based, protein-based, and RNA-based markers provide orthogonal insights that enhance diagnostic confidence and therapeutic alignment. DNA analyses excel at identifying somatic and germline variants; RNA-based assays reveal gene expression patterns and fusion transcripts; and protein-based measurements capture phenotypic states that can predict drug response. Integrating these biomarker classes into composite reports increases clinical actionability but demands harmonized validation and cross-platform comparability.

Based on application, diagnosis, monitoring, prognosis, research, and therapy selection define the primary use cases for profiling technologies. Monitoring use cases such as liquid biopsy and minimal residual disease require assays with exceptional sensitivity and reproducibility, while therapy selection relies on companion diagnostics and pharmacogenomics to match patients to targeted therapies and dosing strategies. Each application imposes different demands on assay design, regulatory documentation, and evidence generation.

Based on end user, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes exhibit distinct operational constraints and value drivers. Diagnostic laboratories prioritize throughput, reproducibility, and reimbursement pathways; hospitals focus on integration with clinical workflows and electronic health records; pharmaceutical companies seek robust biomarker validation and companion diagnostic alignment for drug development; and research institutes emphasize exploratory analyses and novel target discovery. Recognizing these user-specific imperatives is essential for tailoring product design, service models, and commercialization strategies.

A regional perspective on adoption pathways, regulatory variability, and infrastructure requirements that influence equitable access and scale-up of cancer profiling solutions

Regional dynamics play a decisive role in shaping access, adoption rates, and strategic priorities for cancer profiling across the globe. In the Americas, investments in precision oncology infrastructure, widespread adoption of next-generation sequencing, and integrated care networks support rapid clinical translation of novel assays, while market participants must navigate reimbursement complexity and heterogeneous laboratory accreditation landscapes. This region often leads in companion diagnostic collaborations between device makers and pharmaceutical sponsors, producing rich pipelines for implementation studies and real-world evidence generation.

In Europe, Middle East & Africa, heterogeneous regulatory frameworks and variable healthcare financing models create a patchwork of adoption scenarios that favor regionally tailored strategies. High-capacity centers in Western Europe act as hubs for advanced diagnostics and multicenter studies, whereas other subregions prioritize cost-effective assays and scalable workflows that can operate in constrained settings. Cross-border collaborations within Europe are increasingly important for harmonizing standards, enabling data sharing, and accelerating multicountry trials that validate biomarker utility across diverse populations.

In Asia-Pacific, rapid expansion of laboratory capacity, increasing public and private investment in genomics, and large patient populations present substantial opportunities for scaling both diagnostic services and biomarker-driven clinical research. Nevertheless, varying levels of regulatory maturity and differences in reimbursement create a landscape where local partnerships, technology transfer, and capacity building are critical to achieving broad access. Across all regions, supply chain considerations, workforce training, and data governance frameworks will determine the pace and equity of clinical implementation, making regionally informed strategies essential for sustained impact.

How strategic specialization, integrated service models, and collaborative companion diagnostic partnerships define competitive advantage and enable scalable clinical adoption

Leading companies and research organizations are differentiating through specialization, vertically integrated offerings, and collaborative models that combine assay development with informatics and clinical support. Some firms concentrate on platform excellence-delivering validated instruments, consumables, and standardized workflows that enable high-throughput diagnostics-while others focus on niche clinical applications such as minimal residual disease detection or complex structural variant resolution. Strategic partnerships between technology providers and pharmaceutical developers are increasingly common, aligning companion diagnostic development with therapeutic pipelines to streamline regulatory approval and market access.

Competitive dynamics hinge on the ability to demonstrate analytical validity, clinical utility, and operational scalability. Organizations that invest in rigorous multicenter validation studies and interoperable reporting standards gain credibility with laboratories and payers. In addition, companies that provide end-to-end solutions-including sample logistics, bioinformatics, and clinician-facing interpretation-are better positioned to capture value in hospital and laboratory settings that prefer turnkey implementations.

Mergers, acquisitions, and licensing agreements continue to shape the landscape as firms seek to broaden their portfolios and secure access to complementary technologies and regional distribution networks. Simultaneously, a growing cohort of specialized service providers supports research institutes and pharmaceutical companies with bespoke assay development, biomarker validation, and translational analytics. This ecosystem of platform vendors, service providers, and clinical adopters is creating multiple pathways for innovation diffusion, each with distinct implications for pricing, reimbursement negotiation, and long-term sustainability.

Actionable strategic priorities for leaders to build supply resilience, clinical validation pathways, and interoperable services that accelerate uptake and stewardship of profiling solutions

Industry leaders should prioritize investments that reinforce resilience, clinical relevance, and seamless integration into care pathways. Strengthening supply chain transparency and sourcing flexibility will mitigate tariff and logistics risks, while targeted investments in regional manufacturing or distribution can shorten lead times and stabilize access to critical consumables. Concurrently, organizations should invest in cross-platform validation studies that demonstrate concordance between technologies and support interoperability of clinical reports across electronic health systems.

From a product and clinical strategy standpoint, companies should align assay development with high-impact clinical use cases such as therapy selection and minimal residual disease monitoring, producing evidence packages that address payer and clinician requirements. Collaboration with pharmaceutical sponsors for co-development of companion diagnostics and with academic centers for prospective validation studies will accelerate clinical uptake. Equally important is building interpretive services and decision-support tools that translate complex molecular results into actionable clinical recommendations, reducing adoption friction among clinicians.

Operationally, stakeholders must expand workforce training and establish robust quality systems to sustain reproducibility as testing volumes grow. Leaders should also engage proactively with regulators and payers to shape evidence expectations and reimbursement frameworks, emphasizing real-world performance and patient-centric outcomes. Finally, adopting flexible commercial models-ranging from centralized reference testing to reagent-as-a-service-can help organizations tailor offerings to diverse end-user needs and create multiple revenue streams while maintaining patient access.

A transparent and practitioner-focused methodology combining expert engagements, technical literature synthesis, and cross-validation against laboratory standards to ensure actionable insights

The research methodology underpinning this executive summary combined primary and secondary sources, expert interviews, and structured synthesis to produce a balanced assessment of technological, clinical, and commercial trends. Primary inputs included conversations with laboratory directors, clinical investigators, and industry executives to capture operational realities, evidence requirements, and adoption barriers. These qualitative engagements were supplemented by careful review of peer-reviewed literature, regulatory guidance, and technical white papers to ground technological descriptions and clinical use-case delineations.

Analytic approaches emphasized triangulation: cross-referencing expert perspectives with published validation studies and technical specifications to identify consistent patterns of performance and adoption. Particular attention was paid to assay sensitivity, specificity, and workflow compatibility, as well as to logistics such as sample stability and cold chain dependencies. Where possible, methodological choices were benchmarked against established laboratory standards and consensus recommendations to ensure practical relevance.

Limitations of the methodology include potential bias inherent in selective expert sampling and variability in publicly available technical documentation. To mitigate these constraints, the study prioritized sources with direct operational experience and sought corroboration across multiple stakeholder types. The result is a defensible, practitioner-oriented set of insights designed to support strategic decision-making without relying on proprietary market estimates.

Final synthesis underscoring the critical interplay of technology, evidence, and operational resilience that will determine which profiling approaches achieve sustained clinical impact

In conclusion, cancer profiling is at an inflection point where technical advances, regulatory evolution, and shifting supply chain considerations converge to create both opportunities and operational challenges. The most successful organizations will be those that integrate robust assay technology with validated workflows, responsive supply strategies, and clinician-centered reporting that directly support therapeutic decision-making. Emphasizing cross-platform validation and evidence generation will be critical for translating analytical capabilities into routine clinical use.

Moreover, regional heterogeneity and policy dynamics will require adaptive commercial models and sustained stakeholder engagement. By focusing on resilience, clinical alignment, and partnerships that bridge technological and therapeutic development, leaders can accelerate the adoption of high-impact profiling solutions while safeguarding continuity of care. The insights presented here aim to equip senior decision-makers with the context and priorities needed to navigate this evolving landscape and to identify the investments that will yield enduring clinical and commercial value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of circulating tumor DNA liquid biopsy assays for real-time treatment monitoring in oncology
  • 5.2. Implementation of multiomic profiling platforms combining genomics proteomics and metabolomics data for comprehensive tumor characterization
  • 5.3. Regulatory approval trends for next-generation sequencing-based companion diagnostics in targeted cancer therapy selection
  • 5.4. Expansion of artificial intelligence and machine learning algorithms to interpret complex cancer profiling datasets and predict patient outcomes
  • 5.5. Development of cost-effective point-of-care molecular profiling devices for early cancer detection in low-resource settings
  • 5.6. Emergence of epigenetic biomarker panels to stratify patient response to immunotherapy across solid tumor indications
  • 5.7. Partnerships between biopharma and diagnostic companies to co-develop liquid biopsy assays for minimal residual disease monitoring
  • 5.8. Incorporation of spatial transcriptomics into clinical workflows to map tumor microenvironment heterogeneity with high resolution

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Profiling Market, by Cancer Type

  • 8.1. Hematologic Malignancies
    • 8.1.1. Leukemia
    • 8.1.2. Lymphoma
    • 8.1.3. Multiple Myeloma
  • 8.2. Solid Tumors
    • 8.2.1. Breast
    • 8.2.2. Colorectal
    • 8.2.3. Lung
    • 8.2.4. Prostate

9. Cancer Profiling Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Immunohistochemistry
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
    • 9.4.1. Long Read Sequencing
    • 9.4.2. Short Read Sequencing
  • 9.5. Polymerase Chain Reaction

10. Cancer Profiling Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
    • 10.1.3. Whole Blood
  • 10.2. Saliva
  • 10.3. Urine

11. Cancer Profiling Market, by Biomarker Type

  • 11.1. DNA-Based
  • 11.2. Protein-Based
  • 11.3. RNA-Based

12. Cancer Profiling Market, by Application

  • 12.1. Diagnosis
  • 12.2. Monitoring
    • 12.2.1. Liquid Biopsy
    • 12.2.2. Minimal Residual Disease
  • 12.3. Prognosis
  • 12.4. Research
  • 12.5. Therapy Selection
    • 12.5.1. Companion Diagnostics
    • 12.5.2. Pharmacogenomics

13. Cancer Profiling Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Cancer Profiling Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Profiling Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Profiling Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. F. Hoffmann-La Roche AG
    • 17.3.2. Thermo Fisher Scientific Inc.
    • 17.3.3. 4basecare Onco Solutions Private Limited
    • 17.3.4. ACT Genomics Co., Ltd. by Prenetics Global Limited
    • 17.3.5. Agendia, Inc.
    • 17.3.6. Agilent Technologies, Inc.
    • 17.3.7. BostonGene Corporation
    • 17.3.8. Caris Life Sciences
    • 17.3.9. Exact Sciences Corporation
    • 17.3.10. GENINUS Inc.
    • 17.3.11. Genomic Life
    • 17.3.12. GenScript Biotech Corporation
    • 17.3.13. Guardant Health, Inc.
    • 17.3.14. Hologic, Inc.
    • 17.3.15. HTG Molecular Diagnostics, Inc.
    • 17.3.16. Illumina, Inc.
    • 17.3.17. IMBdx, Inc.
    • 17.3.18. Laboratory Corporation of America Holdings
    • 17.3.19. Lucence Health, Inc.
    • 17.3.20. Merck KGaA
    • 17.3.21. NanoString Technologies, Inc.
    • 17.3.22. Neogenomics, Inc.
    • 17.3.23. Nonacus Limited
    • 17.3.24. OncoDNA S.A.
    • 17.3.25. Oncompass Medicine Hungary Kft.
    • 17.3.26. Paragon Genomics, Inc.
    • 17.3.27. Personalis, Inc.
    • 17.3.28. Perthera, Inc.
    • 17.3.29. Qiagen N.V.
    • 17.3.30. Renovaro Biosciences Inc.
    • 17.3.31. Strand Life Sciences
    • 17.3.32. Sysmex Corporation
    • 17.3.33. Takara Bio Inc.
    • 17.3.34. Tempus Labs Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS CANCER PROFILING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER PROFILING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL CANCER PROFILING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL CANCER PROFILING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. CANCER PROFILING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. CANCER PROFILING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER PROFILING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER PROFILING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PROFILING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PROFILING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PROFILING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER PROFILING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER PROFILING MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER PROFILING MARKET SIZE, BY COLORECTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER PROFILING MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER PROFILING MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER PROFILING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER PROFILING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER PROFILING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER PROFILING MARKET SIZE, BY LONG READ SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER PROFILING MARKET SIZE, BY SHORT READ SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER PROFILING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER PROFILING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER PROFILING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER PROFILING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER PROFILING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER PROFILING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER PROFILING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER PROFILING MARKET SIZE, BY DNA-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER PROFILING MARKET SIZE, BY PROTEIN-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER PROFILING MARKET SIZE, BY RNA-BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER PROFILING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER PROFILING MARKET SIZE, BY LIQUID BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER PROFILING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER PROFILING MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CANCER PROFILING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACOGENOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CANCER PROFILING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CANCER PROFILING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CANCER PROFILING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CANCER PROFILING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CANCER PROFILING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CANCER PROFILING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS CANCER PROFILING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS CANCER PROFILING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS CANCER PROFILING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS CANCER PROFILING MARKET SIZE, BY MONITORING, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS CANCER PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS CANCER PROFILING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY THERAPY SELECTION, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA CANCER PROFILING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 312. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2024 (USD MILLION)
  • TABLE 316. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2025-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 318. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 322. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2018-2024 (USD MILLION)
  • TABLE 326. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BLOOD, 2025-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY BIOMARKER TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA CANCER PROFILING MARKET SIZE, BY MONITORING, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA CANCER PROFILING M